Neuropathy, Type 2 Diabetes
Conditions
Keywords
Diabetes mellitus, adverse cardiovascular events, nerve degeneration, peripheral sensory nerves
Brief summary
The study was designed to investigate the correlation between perioperative adverse cardiovascular events and the degeneration of sensory nerves in patient diagnosed with type 2 diabetes mellitus, undergoing elective non-cardiac surgery.
Detailed description
The study was designed to investigate the correlation between perioperative adverse cardiovascular events and the degeneration of sensory nerves in patient diagnosed with type 2 diabetes mellitus, undergoing elective non-cardiac surgery. Diabetes mellitus and peripheral sensory nerve degeneration will be diagnosed via clinical evaluation. Serum levels of constituent neuropeptides, including neuropeptide Y (NPY), calcitonin and substance P (SP) and calcitonin gene related peptide (CGRP), and transient receptor potential vanilloid 1 (TRPV1), a molecular nociceptor in peripheral sensory nerves will be quantitatively evaluated. The clinical and the biochemical consequence will be compared between the cohorts of diabetic and non-diabetic patients. The differences and the correlations will be analyzed. The results of the study may reveal whether or not the perioperative adverse cardiovascular events in diabetic patients are correlated with degeneration of peripheral sensory nerves and the alterations in the neuropeptides and TRPV1 are potentially applicable for evaluation of the risk of cardiovascular events in perioperative period in diabetic patients.
Interventions
PROCEDUREnon-cardiac surgery
All the patients are undergoing non-cardiac surgery.
Sponsors
Second Hospital of Shanxi Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* The main discharge diagnosis is T2DM； * Age \> 18 years old; * No acute complications of diabetes
Exclusion criteria
* T1DM patients; * EGFR \< 60 ml/min/1.73 m or proteinuria (or both); * Patients with history of acute cardiovascular events; * Familial hypercholesterolemia or other hereditary lipid metabolism diseases; * anti-HIV patients; * Patients with serious mental health problems; * Patients receiving drugs that can lead to dyslipidemia, such as antipsychotics, corticosteroids, or immunosuppressants; * Patients with systemic inflammatory diseases, such as systemic lupus erythematosus; * Patient are quitting smoking and severe obesity (BMI\>40)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| adverse cardiovascular events | Perioperative period | All the pre-, intra- and post-operative adverse cardiovascular events in the patients will be taken into account. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| NPY, CGRP, SP and TRPV1 | Perioperative period | The difference in the serum levels of NPY, CGRP, SP and TRPV1 |
Countries
China
Contacts
Primary ContactZheng Guo, M.B., Ph.D.
Outcome results
None listed